
Chordate Medical Holding Investor Relations Material
Latest events

Q3 2024
Chordate Medical Holding

Q1 2025
23 May, 2025

Q4 2024
28 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Chordate Medical Holding
Access all reports
Chordate Medical Holding AB is a medical technology company that has developed and patented Ozilia Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The company focuses on providing solutions for patients suffering from chronic nasal congestion and chronic migraine, aiming to offer effective and non-pharmacological treatment options. The company is headquartered in Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
CMH
Country
🇸🇪 Sweden